NCT01902173 2025-01-14Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerNational Cancer Institute (NCI)Phase 1/2 Completed27 enrolled 16 charts
NCT02097225 2024-10-16Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1 Terminated22 enrolled 21 charts